文献速递头颈部肿瘤放疗放疗物理与技术

头颈部肿瘤联合碘-131放射配体治疗与外照射放疗的体素级剂量学研究

Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-02-16

本研究针对复发头颈部癌患者,在1期临床试验中建立个体化剂量学框架,将CLR 131(含碘-131的放射配体治疗药物)的蒙特卡洛剂量学与外照射放疗剂量学在体素水平通过可变形图像配准融合。结果显示配准方法一致性良好,最大平均吸收剂量差异为-11.2%,联合治疗靶区吸收剂量范围为57.14至75.02 Gy。

要点

  • 可变形图像配准在肿瘤体积内活度浓度和吸收剂量上一致性良好,最大平均吸收剂量差异-11.2%。
  • 基于放射配体治疗吸收剂量计算,患者外照射放疗减少了2至4次分次。
  • 联合治疗靶区吸收剂量范围为57.14至75.02 Gy。

核心结论

  • 本工作证明了在治疗计划CT扫描上实施外照射放疗联合放射配体治疗剂量学的临床可行性。

研究设计与样本

  • 研究为1期临床试验中纳入的复发头颈部癌患者建立个体化剂量学框架,联合外照射放疗与放射配体治疗。
  • 患者注射577.2 MBq/m2(15.6 mCi/m2)CLR 131后约24、48、72和168小时行系列单光子发射计算机断层扫描/计算机断层扫描。
  • 使用RayStation基于治疗计划CT创建临床外照射放疗计划,通过3D Slicer中Elastix可变形图像配准模块将SPECT/CT图像配准至治疗计划CT。
  • 外照射放疗剂量学采用EGSnrc蒙特卡洛计算,放射配体治疗剂量学采用基于GEANT4的RAPID平台。
  • 使用生物有效剂量和2 Gy分次等效剂量等放射生物学指标联合两种放疗模式。

主要发现

  • 可变形图像配准方法在SPECT/CT与治疗计划CT图像的肿瘤体积内活度浓度和计算吸收剂量上一致性良好,最大平均吸收剂量差异为-11.2%。
  • 基于放射配体治疗吸收剂量计算,从患者外照射放疗中移除了2至4次分次。
  • 联合治疗中靶区体积的吸收剂量范围为57.14至75.02 Gy。
  • 纳入部分体积校正后,外照射放疗联合放射配体治疗对计划靶区的平均2 Gy分次等效剂量与单纯外照射放疗相比差异为-3.11%至1.40%。

临床怎么用

  • 剂量学指导外照射放疗的治疗决策,本工作为在快速兴起的临床放射配体治疗领域实施同一范式提供了桥梁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment for patients with recurrent head and neck cancer. This work establishes a patient-specific dosimetry framework that combines Monte Carlo-based dosimetry from the 2 radiation modalities at the voxel level using deformable image registration (DIR) and radiobiological constructs for patients enrolled in a phase 1 clinical trial combining EBRT and RPT. METHODS AND MATERIALS: Serial single-photon emission computed tomography (SPECT)/computed tomography (CT) patient scans were performed at approximately 24, 48, 72, and 168 hours postinjection of 577.2 MBq/m2 (15.6 mCi/m2) CLR 131, an iodine 131-containing RPT agent. Using RayStation, clinical EBRT treatment plans were created with a treatment planning CT (TPCT). SPECT/CT images were deformably registered to the TPCT using the Elastix DIR module in 3D Slicer software and assessed by measuring mean activity concentrations and absorbed doses. Monte Carlo EBRT dosimetry was computed using EGSnrc. RPT dosimetry was conducted using RAPID, a GEANT4-based RPT dosimetry platform. Radiobiological metrics (biologically effective dose and equivalent dose in 2-Gy fractions) were used to combine the 2 radiation modalities. RESULTS: The DIR method provided good agreement for the activity concentrations and calculated absorbed dose in the tumor volumes for the SPECT/CT and TPCT images, with a maximum mean absorbed dose difference of -11.2%. Based on the RPT absorbed dose calculations, 2 to 4 EBRT fractions were removed from patient EBRT treatments. For the combined treatment, the absorbed dose to target volumes ranged from 57.14 to 75.02 Gy. When partial volume corrections were included, the mean equivalent dose in 2-Gy fractions to the planning target volume from EBRT + RPT differed -3.11% to 1.40% compared with EBRT alone. CONCLUSIONS: This work demonstrates the clinical feasibility of performing combined EBRT + RPT dosimetry on TPCT scans. Dosimetry guides treatment decisions for EBRT, and this work provides a bridge for the same paradigm to be implemented within the rapidly emerging clinical RPT space.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Adam DP, Grudzinski JJ, Marsh IR, et al. Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38367914. doi:10.1016/j.ijrobp.2024.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。